Access to Life-Saving Medicine Act

Bill: 110-hr-1038
Sponsor: Rep. Waxman, Henry A. [D-CA-30]
Introduced: 2007-02-14 in the House
Policy area: Health
Subjects: Administrative remedies
Civil actions and liability
Clinical trials
Commerce
Congressional reporting requirements
Department of Health and Human Services
Drug approvals
Drug industry
Food and Drug Administration (FDA)
Government Operations and Politics
Injunctions
Intellectual property
Judicial opinions
Judicial review
Labeling
Law
Licenses
Patent infringement
Patents
Pharmaceutical research
Product safety
Science, Technology, Communications

Summary:
action_date: 2007-02-14
text: 
Access to Life-Saving Medicine Act - Amends the Public Health Service Act to establish a process for the approval of an abbreviated biological product application for products that contain the same or similar active ingredients as a previously licensed biological product (the reference product). Allows a person to file an abbreviated biological product application with the Secretary of Health and Human Services that includes: (1) data demonstrating that the product is comparable to or interchangeable with the reference product; (2) information to show that the conditions or conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product; and (3) information to show that the route of administration, the dosage form, and the strength of the biological product are the same as those of the reference product.
 
Sets forth conditions for approval of such an application by the Secretary.
 
Allows an applicant to request that the Secretary make a determination as to the interchangeability of a comparable product and the reference product based on whether a product can be expected to produce the same clinical result as the reference product in any given patient. Provides market exclusivity to such an interchangeable product. Requires the Secretary to defer issuing a determination of interchangeability for a subsequent comparable biological product during the period of market exclusivity for a prior interchangeable comparable biological product.
 
Requires the Secretary to establish requirements for the efficient review, approval, suspension, and revocation of comparable biological product applications.
 
Sets forth provisions governing patent infringement claims against an applicant or prospective applicant for a comparable biological product license. 


Legislative actions:
action_date: 2007-02-15
text: Referred to the Subcommittee on Health.
action_date: 2007-02-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-02-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-02-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2007-02-14
text: Introduced in House
action_date: 2007-02-14
text: Introduced in House